ArticleHereditas2026
Folate-driven changes in snoRNA function: a novel epigenetic-ribosomal axis in hepatocellular carcinoma.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Folate (FA), essential for DNA synthesis, repair and methylation, is predominantly stored and metabolized in the liver. Dysregulation of folate intake and metabolism is strongly implicated in the pathogenesis of hepatocellular carcinoma (HCC). Although small nucleolar RNAs (snoRNAs) have shown promise as diagnostic and prognostic biomarkers in HCC, the impact of folate deficiency on their expression landscape remains uncharacterized. Here, by performing snoRNA-seq in folate-deficient HepG2 cells, we systematically identified 26 differentially expressed snoRNAs for the first time. Functional enrichment analysis indicated that downregulated snoRNAs were closely associated with cell proliferation pathways. From these, we selected SNORD1B, highly expressed in HCC tissues, correlated with poor prognosis, and significantly suppressed upon 28-day FA deprivation for mechanistic investigation. We demonstrated that FA deficiency coordinately downregulated SNORD1B and its host gene SNHG16 (P < 0.05), with strong positive correlation (R2 = 0.5104, P = 0.0465). This downregulation led to markedly reduced 2′-O-methylation at the G4362 site of 28S rRNA (P < 0.01) and impaired ribosomal activity. Expression of snoRNA-binding proteins (FBL, NOP58, NOP56) as well as IL-6 and CDK1 were significantly suppressed (P < 0.05), alongside decreased TP53 protein levels (P < 0.001). Functional assays confirmed that FA deficiency potently inhibited HepG2 proliferation and migration (P < 0.01). Our findings reveal a previously unrecognized mechanism: folate deficiency attenuates SNORD1B-dependent 2′-O-methylation of 28S rRNA, resulting in ribosomal dysfunction and suppression of global protein synthesis, thereby inhibiting HCC cell proliferation and migration. This study provides novel insight into the epigenetic-ribosomal axis of FA-mediated tumor suppression and highlights snoRNAs as potential therapeutic targets in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.